

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Serial No. 10/030,186

Response to Office communication of October 29, 2003

REMARKS

Claim 1 has been amended by introducing the following definitions:-

R₂ from page 16, line 24 to page 18, line 11 of the specification;

R₁ from page 19, lines 4 to 20 of the specification;

R_{1j} from page 19, line 21 to page 20, line 2 of the specification;

-X-X- from Claim 10 (see also page 7, lines 5 to 6);

Y from Claim 11 (see also page 7, lines 11 to 12);

Cy from Claim 12 (see also page 10, lines 8 to 16);

and

R_{3a} from Claim 14 and page 10, line 27 to page 12, line 3 of the specification.

Claims 6, 7, 10, 11, 12 and 14 have been deleted as a consequence.

Claim 2 has been amended by introducing the definition of Cy from Claim 13 and of R_{3a} from Claim 17. It is noted that Claims 13 and 17 were originally drafted in multiple dependent form, and thus depended *inter alia* from Claim 2. These amendments are intended to ensure that all of the features of Claim 2 are entitled to the first priority date claimed under 35 U.S.C. § 119.

Claims 13, 15 and 17 have been deleted as a consequence of the amendment to Claim 2.

Claim 20 has been amended to take account of the limitation of the definition of Y in Claim 1. The claim has also been returned to multiple dependent form.

Claim 24 has been amended to recite the thrombotic disorders listed at page 2, lines 20 to 24 of the specification.

Serial No. 10/030,186

Response to Office communication of October 29, 2003

Claim 27, R_{1b} in the formula NH₂-CR_{1b}(Cy)-COOH has been replaced with H, consistent with the definition of Y as CH.

ELECTION/RESTRICTIONS

Applicants notes with appreciation that the Examiner's search has been extended to cover the whole genus.

CLAIM REJECTIONS - 35 U.S.C. § 112, FIRST PARAGRAPH

Claims 1-13, 16-21, 24 and 27-31 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly being enabled only in respect of certain of the possible values for R₂ and L-Lp(D)_n.

While not necessarily agreeing with the Examiner, it is respectfully submitted that the claims as presently amended do satisfy the requirements of 35 U.S.C. § 112, first paragraph.

Applicants have invented the compounds defined in the present claims. They have described what the compounds are, how they may be prepared and what they are useful for.

It is respectfully submitted that the disclosure (including the working examples) of PCT/GB00/02302 (WO 00/76971), from which the present application claims priority under 35 U.S.C. § 119, is consistent with the way in which Applicants have defined R₂ and L-Lp(D)_n in the claims as amended.

CLAIM REJECTIONS - 35 U.S.C. § 112, SECOND PARAGRAPH

Claims 1 and 24 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly being enabled in respect of certain of the possible values for R₂ and L-Lp(D)_n.

While not necessarily agreeing with the Examiner, it is respectfully submitted that the claims as presently amended

Serial No. 10/030,186

Response to Office communication of October 29, 2003

do satisfy the requirements of 35 U.S.C. § 112, second paragraph.

It is respectfully submitted that the term "in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative" is clear. Reference is made to the attached copy of a relevant section from the IUPAC nomenclature guide, which describes how the term "didehydro" is used in subtractive nomenclature to signify removal of a hydrogen pair from the saturated ring so as to indicate the presence of a double bond.

If the Examiner still has concerns about Applicants' use of the term "a 3,4-didehydro derivative", he is kindly requested to contact the undersigned directly, so that an alternative form of wording can be agreed.

CLAIM REJECTIONS - 35 U.S.C. § 103(A)

Claims 1-5, 10-13, 21 and 24 stand rejected under 35 U.S.C. 103(a) as allegedly being unpatentable in view of Liebeschuetz et al., (WO 99/11657). Particular reference is made to the compound of Example 54.

While not necessarily agreeing with the Examiner, it is respectfully submitted that the claims as amended comply with 35 U.S.C. 103(a).

Liebeschuetz et al., do not disclose compounds having the particular L-Lp(D)_n group possessed by the presently-claimed compounds. The compound of Example 54 differs from the presently-claimed compounds in lacking a methylene group corresponding with Q, and in having a 1-aminoisoquinoline group corresponding with R₂.

CLAIM OBJECTIONS

Claim 11 stands objected to under 37 C.F.R. 1.75(c) as allegedly being in improper multiple dependent form.

Serial No. 10/030,186

Response to Office communication of October 29, 2003

This objection is believed to be moot, since Claim 11 has been deleted.

It is respectfully submitted that Claim 20 as amended is now in proper, multiple dependent form.

INFORMATION DISCLOSURE STATEMENT

The Examiner has indicated that copies of several references cited in Applicants' Information Disclosure Statement are not available to him. The undersigned contacted the Examiner by telephone on January 26, 2004, and understands that these references are still unavailable.

The references were hand-delivered in a box to the USPTO on July 14, properly referenced to the present application, and a postcard receipt bearing the stamp of the Patent and Trademark Office was mailed back to the undersigned.

The undersigned will try to track down the references for the Examiner, and if necessary will resubmit copies. The Examiner is kindly requested to await the references before disposing of the application. They may just be taking a long time to get scanned.


COMMUNICATION BY TELEPHONE

The undersigned's office is located in the United Kingdom, which is five hours ahead of the USPTO, and hence the Examiner may have difficulty contacting him from the USPTO by telephone. If the Examiner wishes to speak with the undersigned by telephone, he can contact the undersigned by e-mail at martinahay@martin-a-hay.com, or leave a message with Linda McDonald of Eli Lilly and Company at (317) 433 7140. The undersigned will then call the Examiner.

Serial No. 10/030,186

Response to Office communication of October 29, 2003

Respectfully submitted,


Hay, Martin Alexander
Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

e-mail: martinahay@martin-a-hay.com

Martin A. Hay & Co.,
13 Queen Victoria Street
Macclesfield
Cheshire
SK11 6LP
UNITED KINGDOM

January 28, 2004